Cargando…

Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

The objective of this study was to evaluate the cost-effectiveness of posaconazole versus fluconazole for the prevention of invasive fungal infections (IFI) in graft-versus-host disease (GVHD) patients in the Netherlands. A decision analytic model was developed based on a double-blind randomized tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Jeroen P., O’Sullivan, Amy K., Lugtenburg, Elly, Span, Lambert F. R., Janssen, Jeroen J. W. M., Stam, Wiro B.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908442/ https://www.ncbi.nlm.nih.gov/pubmed/20383504 http://dx.doi.org/10.1007/s00277-010-0939-8

Ejemplares similares

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
por: Resende, C.B., et al.
Publicado: (2017)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
por: Grau, Santiago, et al.
Publicado: (2012)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
por: Mhandire, Kudakwashe, et al.
Publicado: (2021)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial
por: Mersal, Ali, et al.
Publicado: (2013)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD)
por: Demosthenous, Christos, et al.
Publicado: (2021)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

Editorial: Novel and Improved Methods for the Prevention and Treatment of Graft-Versus-Host Disease (GVHD)
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation
por: Czech, Marie, et al.
Publicado: (2022)

The development of graft-versus-host disease prophylaxis
por: Cutler, Corey
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease (GVHD)
por: Qian, Liren, et al.
Publicado: (2013)

Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD): The First Reported Use in Pediatric Patients
por: Gagliardi, Thomas A, et al.
Publicado: (2022)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

Thiol/Redox Metabolomic Profiling Implicates GSH Dysregulation in Early Experimental Graft versus Host Disease (GVHD)
por: Suh, Jung H., et al.
Publicado: (2014)

Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation
por: Chen, Xinhua, et al.
Publicado: (2016)

Self-retained cryopreserved amniotic membrane in treating acute ocular graft-versus-host-disease (oGVHD)
por: Yin, Han Y., et al.
Publicado: (2020)

(18)F-FDG-PET-MRI for the assessment of acute intestinal graft-versus-host-disease (GvHD)
por: Roll, Wolfgang, et al.
Publicado: (2021)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection
por: Faisal, Muhammad Salman, et al.
Publicado: (2022)

Development and validation of a diagnostic model for the identification of chronic ocular graft-versus-host disease (oGVHD)
por: Shen, Zhan, et al.
Publicado: (2023)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients
por: Shidham, Vinod B, et al.
Publicado: (2003)

Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults
por: Poiret, Thomas, et al.
Publicado: (2014)

Erratum to: Cytokine and human leukocyte antigen (HLA) profile for graft-versus-host disease (GVHD) after organ transplantation
por: Chen, Xinhua, et al.
Publicado: (2017)

Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?
por: Rozmus, Jacob, et al.
Publicado: (2022)

Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
por: Dahlén, Torsten, et al.
Publicado: (2015)

Fluconazole prophylaxis in preterm infants: a systematic review
por: Rios, Juliana Ferreira da Silva, et al.
Publicado: (2017)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cvubshoae3un6thhkphdnrnq49